Following early advantages with transcatheter aortic valve replacement (TAVR) vs surgery (SAVR), outcomes for severe aortic stenosis patients at low surgical risk equalized between the two treatment paradigms in the longer term, a 7-year follow-up of the PARTNER 3 study has found. 

Patients with acute myocardial infarction (AMI) who are at risk of developing cardiogenic shock (CS) in the hospital after percutaneous coronary intervention (PCI) do not see a reduction in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels from early dobutamine infusion, though systolic blood pressure (BP) does decrease. 

The Evolut Low-Risk trial 6-year results showed no significant differences in death or adverse outcomes between transcatheter aortic valve replacement (TAVR) versus surgery for patients with severe aortic stenosis (AS) at low risk for surgery. 

Early interleukin-6 receptor inhibition with tocilizumab safely suppressed systemic inflammation but did not reduce peak NT-proBNP or left ventricular infarct size in patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), according to new data from the DOBERMANN-T trial. 

The use of a sirolimus-eluting balloon (SEB) with provisional stenting results in one-year outcomes that are comparable to systematic drug-eluting stent (DES) implantation for the treatment of de novo coronary lesions, according to findings presented by Christian Spaulding, MD, PhD. 

Clopidogrel monotherapy given during the chronic maintenance period after percutaneous coronary intervention (PCI) with drug eluting stents (DES) carried significantly lower risk for high-risk patients compared with aspirin monotherapy, according to a new widescale Chinese study. 

The Trisol transcatheter tricuspid valve replacement (TTVR) device is safe and effective in treating patients with tricuspid regurgitation (TR) and improves clinical outcomes at 12 months post-procedure, early feasibility study (EFS) results show.

The Laplace transcatheter tricuspid valve replacement (TTVR) system demonstrates encouraging early safety and promising clinical improvements in patients with severe tricuspid regurgitation (TR), according to updated results from an ongoing U.S.-based early feasibility study (EFS). 

A novel balloon-expandable transcatheter aortic valve implantation (TAVI) system provides a safe and effective treatment approach for patients with symptomatic severe aortic stenosis, according to the latest data presented at the Cardiovascular Research Technologies (CRT) 2026 meeting.